CPIX CUMBERLAND PHARMACEUTICALS INC

NEUTRAL Impact: 3/10 DEFA14A
Horizon days Filed Mar 9, 2026 Processed 3mo ago SEC 0001087294-26-000027
Proxy solicitation materials
Final — all horizons settled through T+60d
CPIX ▲ +77.53% at T+60d
NEUTRAL call ✓ call won +77.53% · α vs SPY +65.85% · entry $3.16 → $5.61
Currently $5.72 · +81.01% from $3.16 entry
Entry anchored
Mar 9, 03:51 PM ET
via Databento tick
T+1d
-2.53%
call -2.53% · α -2.43%
$3.08
settled 3mo ago
T+5d
-4.75%
call -4.75% · α -3.84%
$3.01
settled 3mo ago
T+20d
-0.63%
call -0.63% · α -0.48%
$3.14
settled 2mo ago
T+60d
+77.53%
call +77.53% · α +65.85%
$5.61
settled 7d ago

Price Chart

Loading chart...

Executive Summary

Cumberland Pharmaceuticals Inc. (CPIX) filed a Definitive Additional Proxy Statement (DEFA14A) for its 2026 Annual Meeting of Shareholders, scheduled for April 21, 2026. The filing solicits votes on the re-election of two director nominees (Kenneth Krogulski and Caroline Young), ratification of the appointment of Carr, Riggs Ingram, L.L.C. as independent auditors, advisory approval of executive compensation, and the frequency of future advisory votes on executive pay. The board recommends voting in favor of all proposals.

Actionable Insight

No immediate trading implications. Monitor for any unexpected opposition or shareholder activism ahead of the vote, though none is indicated in this filing. The next material event to watch is the company's 2025 Form 10-K, referenced in the proxy materials.

Key Facts

  • Annual meeting date: April 21, 2026
  • Record date for voting: February 27, 2026
  • Director nominees: Kenneth Krogulski and Caroline Young
  • Proposal to ratify Carr, Riggs Ingram, L.L.C. as independent auditors
  • Advisory vote on executive compensation (say-on-pay)
  • Advisory vote on frequency of say-on-pay votes (board recommends every three years)
  • Filed by the registrant (company management)

Financial Impact

No direct financial impact from the proxy proposals

Risk Factors

  • Low risk of shareholder opposition given routine nature of proposals
  • Potential for future governance concerns if executive compensation becomes excessive relative to performance

Market Snapshot

Exchange
Nasdaq

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
DEFA14A Filing (Primary)0001087294-26-000027
Document: 0001087294-26-000027-index-headers.html0001087294-26-000027
Document: 0001087294-26-000027-index.html0001087294-26-000027
Document: 0001087294-26-000027.txt0001087294-26-000027
3 reports for CPIX
Performance horizon

Track record builds as more directional reports settle.

Filters
Rows
Reports for CPIX — sortable, filterable
Type Now
May 26, 2026
14d ago
DEFM14A
BULLISH ★ 7/10
$5.77 $5.77· 0.00%▼ −1.21%$5.72 (−0.87%)
Apr 23, 2026
6w ago
DEFA14A / 8-K
BULLISH ★ 7/10
$3.90 $4.21▲ +7.95%▲ +6.47%$5.72 (+46.67%)
Mar 9, 2026
13w ago
DEFA14A
NEUTRAL ★ 3/10
$3.16 $3.01▼ −4.75%▼ −3.84%$5.72 (+81.01%)
Showing 3 of 3

US Market Status

Market Closed — Opens Thu (11h 12m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access